Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide

AAPS Journal

Volumn 16, Issue 4, 2014, Pages 736-748

  Varma, Manthena V S ^a   Scialis, Renato J ^a   Lin, Jian ^a   Bi, Yi An ^a   Rotter, Charles J ^a   Goosen, Theunis C ^a   Yang, Xin ^a  

^a PFIZER INC   (United States)

Author keywords

CYP2C9; drug drug interaction; glyburide; OATP1B1; physiologically based pharmacokinetic model

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; GLIBENCLAMIDE; MICROSOME ENZYME; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B2; ANTIDIABETIC AGENT; ENZYME INHIBITOR; ISOENZYME; ORGANIC ANION TRANSPORTER;

ACTIVE TRANSPORT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MECHANISM; DRUG UPTAKE; EMBRYO; ENZYME BINDING; GENETIC VARIABILITY; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; LIVER CELL CULTURE; PASSIVE TRANSPORT; PHARMACOGENETICS; PREDICTION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CACO 2 CELL LINE; COMPUTER SIMULATION; DRUG INTERACTION; ENZYME SPECIFICITY; GENETICS; LIVER CELL; METABOLISM;

CACO-2 CELLS; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; GLYBURIDE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; SUBSTRATE SPECIFICITY;

EID: 84903633472     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9614-7     Document Type: Article

References (68)

1. Rydberg T, Jonsson A, Melander A. Comparison of the kinetics of glyburide and its active metabolites in humans. J Clin Pharm Ther. 1995;20(5):283-95.
2. Zharikova OL, Ravindran S, Nanovskaya TN, Hill RA, Hankins GD, Ahmed MS. Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon. Biochem Pharmacol. 2007;73(12):2012- 9.
3. Ravindran S, Zharikova OL, Hill RA, Nanovskaya TN, Hankins GD, Ahmed MS. Identi fi cation of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem Pharmacol. 2006;72(12):1730- 7.
4. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care. 1994;17(9):1026-30. (Pubitemid 24268615)
5. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72(3):326-32.
6. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002;71(4):286-96. (Pubitemid 34311458)
7. Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther. 2005;78(4):370-7. (Pubitemid 41393672)
8. Ieiri I, Fukae M, Maeda K, Ando Y, Kimura M, Hirota T, et al. Pharmacogenomic/pharmacokinetic assessment of a fourprobe cocktail for CYPs and OATPs following oral microdosing. Int J Clin Pharmacol Ther. 2012;50(10):689 - 700.
9. Zharikova OL, Fokina VM, Nanovskaya TN, Hill RA, Mattison DR, Hankins GD, et al. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol. 2009;78(12):1483-90.
10. Zhou L, Naraharisetti SB, Liu L, Wang H, Lin YS, Isoherranen N, et al. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos. 2010;31(4):228- 42.
11. Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica Fate Foreign Compd Biol Syst. 2004;34(5):415-27. (Pubitemid 38901452)
12. Koenen A, Kock K, Keiser M, Siegmund W, Kroemer HK, Grube M. Steroid hormones specifically modify the activity of organic anion transporting polypeptides. Eur J Pharm Sci. 2012;47(4):774-80.
13. Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85(1):78-85.
14. Appel S, Rufenacht T, Kalafsky G, Tetzloff W, Kallay Z, Hitzenberger G, et al. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol. 1995;76(2):29A-32A.
15. Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol. 2007;63(6):732- 40.
16. Semple CG, Omile C, Buchanan KD, Beastall GH, Paterson KR. Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol. 1986;22(2):187-90. (Pubitemid 17174117)
17. Fleishaker JC, Phillips JP. Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers. J Clin Pharmacol. 1991;31(3):259-62.
18. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther. 2011;90(4):575-81.
19. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V. Mechanistic modeling to predict the transporter- and enzymemediated drug-drug interactions of repaglinide. Pharm Res. 2013;30(4):1188-99.
20. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81(2):194-204. (Pubitemid 46174816)
21. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819-50. (Pubitemid 36995083)
22. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36(1):164-72. (Pubitemid 34700774)
23. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther. 2001;69(6):400-6. (Pubitemid 32554545)
24. Huang SM, Rowland M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther. 2012;91(3):542- 9.
25. Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos. 2009;37(8):1587-97.
26. Greupink R, Schreurs M, Benne MS, Huisman MT, Russel FG. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. Eur J Pharm Sci. 2013;49(5):819-28.
27. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol. 2013.
28. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004;32(6):647-60. (Pubitemid 38668158)
29. Adachi Y, Suzuki H, Sugiyama Y. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm Res. 2003;20(8):1163-9. (Pubitemid 36951840)
30. Kalgutkar AS, Chen D, Varma MV, Feng B, Terra SG, Scialis RJ, et al. Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5- (N -(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2- methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha. Xenobiotica Fate Foreign Compd Biol Syst. 2013;43(11):963-72.
31. Bi YA, Kazolias D, Duignan DB. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos. 2006;34(9):1658-65. (Pubitemid 44285409)
32. Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36(7):1385-405. (Pubitemid 351929323)
33. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53(3):1098-108.
34. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238-57. (Pubitemid 43874439)
35. Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami- Hodjegan A, et al. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet. 2014;53(1):73-87.
36. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res. 2012;29(10):2860-73.
37. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, et al. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm. 2012;9(12):3535-42.
38. Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, et al. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos. 2013;41(5):966-74.
39. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34(7):1229-36.
40. Almond LM, Rowland-Yeo K, Howgate EM, Dickinson GL, Tucker GT, Rostami-Hodjegan A. Prediction of the oral clearance of tolbutamide in individuals with different CYP2C9 genotypes using in vitro enzyme kinetic data. Drug Metab Rev. 2006;38:S209-10.
41. Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br J Clin Pharmacol. 2007;64(1):14-26. (Pubitemid 46934416)
42. Kleist P, Ehrlich A, Suzuki Y, Timmer W, Wetzelsberger N, Lucker PW, et al. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol. 1997;53(2):149-52. (Pubitemid 27491669)
43. Neugebauer G, Betzien G, Hrstka V, Kaufmann B, von Mollendorff E, Abshagen U. Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). Int J Clin Pharmacol Ther Toxicol. 1985;23(9):453-60. (Pubitemid 15232188)
44. Liu L, Pang KS. The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos. 2005;33(1):1-9. (Pubitemid 40023507)
45. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27(5):425-46. (Pubitemid 43363338)
46. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007-17.
47. Menochet K, Kenworthy KE, Houston JB, Galetin A. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos. 2012;40(9):1744-56.
48. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652-62.
49. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, et al. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol. 2013;9(4):459-72.
50. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther. 2013;94(1):64-79.
51. USFDA. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. Center for Drug Evaluation and Research (CDER). 2012.
52. Camenisch G, Umehara K. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions. Biopharm Drug Dispos. 2012;33(4):179-94.
53. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26(9):2039-54.
54. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581-7.
55. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000;157(5):1575-80.
56. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan RY. Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. Drug Metabol Drug Interact. 2003;19(4):287-95. (Pubitemid 38116498)
57. Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008;47(10):669-80.
58. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006;34(5):880-6.
59. Wang R, Chen K, Wen SY, Li J, Wang SQ. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther. 2005;78(1):90-2. (Pubitemid 40956936)
60. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther. 2003;74(2):186-94. (Pubitemid 36951816)
61. Choi CI, Kim MJ, Chung EK, Lee HI, Jang CG, Bae JW, et al. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol. 2012;68(2):149-54.
62. Cheng Y, Wang G, Zhang W, Fan L, Chen Y, Zhou HH. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur J Clin Pharmacol. 2013;69(3):407-13.
63. Yoshida K, Maeda K, Sugiyama Y. Transporter-mediated drug- drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther. 2012;91(6):1053-64.
64. Toda T, Eliasson E, Ask B, Inotsume N, Rane A. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009;105(5):327-32.
65. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000;56(3):225-9. (Pubitemid 30456682)
66. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46(1):49-53. (Pubitemid 28308424)
67. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 2010;38(2):215-22.
68. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157-81.